MARKET

JNJ

JNJ

Johnson&Johnson
NYSE

Real-time Quotes | Nasdaq Last Sale

145.66
+0.99
+0.68%
After Hours: 146.00 +0.34 +0.23% 19:41 09/25 EDT
OPEN
144.00
PREV CLOSE
144.67
HIGH
146.25
LOW
143.89
VOLUME
5.53M
TURNOVER
--
52 WEEK HIGH
157.00
52 WEEK LOW
109.16
MARKET CAP
383.50B
P/E (TTM)
25.61
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
Biotech stock reversed course last week, dragged lower by the broader market weakness.
Benzinga · 1h ago
Novavax stock soars after start of late-stage COVID-19 vaccine trial
Novavax’s stock price surged Friday after the biotech firm started a key late-stage trial of its experimental coronavirus vaccine.
marketwatch.com · 4h ago
Retirement: The Near-Perfect Portfolio Revisited
We introduced the concept of the Near Perfect Portfolio earlier this year. Since then, the market has made a remarkable comeback. It's probably time to revisit it.For most people, especially retirees, it's very difficult to tolerate large and deep drawdowns. But with index investing, there's no escape from a roller coaster ride.The principles of NPP revolve around sustainable income, low drawdowns, capital preservation, and reasonable growth over the long term.We define a Near-Perfect Portfolio as the one that has low volatility, goes up in a good market, conserve capital in a bad market, and provides at least 5% income.
Seekingalpha · 6h ago
5 Dividend Aristocrats To Buy And 5 Dividend Aristocrats To Avoid
Dividend Aristocrats can be a source of growing income and have outperformed during downturns.Not all of them are necessarily attractively valued at the same time, however.Taking a closer look at each individual stock could lead to higher returns compared to just buying the ETF.
Seekingalpha · 6h ago
Point/Counterpoint: The Case for Peloton
By Geoffrey Smith  and Peter Nurse
Investing.com · 11h ago
Dr. Scott Gottlieb: FDA's new guidelines are in line with expectations
The FDA said it plans to release stricter guidelines on vaccine emergency use authorization. Dr. Scott Gottlieb, former FDA commissioner, joins 'Closing Bell' to discuss.
CNBC.com · 22h ago
Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial
A single dose of Johnson & Johnson's experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on Friday. A single shot, versus a rival two-dose approach being tested by Moderna Inc
Reuters · 23h ago
BiomX: A Phage Platform Play
BiomX is focused on large market opportunities using the unique approach of manipulating the microbiome utilizing phage therapy.BX001 will begin Phase II trials in 2021 in acne and if successful, marketing will be handled by a global cosmetic company.BX002 will enter the clinic in 2020 in a Phase 1 study in inflammatory bowel disease with a data read out by year end.BiomX is a high risk, high return investment only suitable for investors seeking this profile.
Seekingalpha · 23h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JNJ. Analyze the recent business situations of Johnson&Johnson through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JNJ stock price target is 165.06 with a high estimate of 180.00 and a low estimate of 142.00.
EPS
Institutional Holdings
Institutions: 2.90K
Institutional Holdings: 1.98B
% Owned: 75.25%
Shares Outstanding: 2.63B
TypeInstitutionsShares
Increased
1.10K
197.25M
New
84
2.11M
Decreased
1.26K
50.31M
Sold Out
67
5.44M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/Director
Alex Gorsky
Vice Chairman - Management/Chief Scientific Officer
Paulus Stoffels
Vice Chairman - Management
Joaquin Duato
Chief Financial Officer/Executive Vice President
Joseph Wolk
Chief Human Resource Officer/Executive Vice President
Peter Fasolo
Executive Vice President/General Counsel
Michael Ullmann
Executive Vice President
Ashley McEvoy
Executive Vice President
Thibaut Mongon
Executive Vice President
Michael Sneed
Executive Vice President
Jennifer Taubert
Executive Vice President
Kathryn Wengel
Lead Director/Independent Director
Anne Mulcahy
Independent Director
Mary Beckerle
Independent Director
D. Scott Davis
Independent Director
Ian Davis
Independent Director
Jennifer Doudna
Independent Director
Marillyn Hewson
Independent Director
Hubert Joly
Independent Director
Mark McClellan
Independent Director
Charles Prince
Independent Director
A. Eugene Washington
Independent Director
Mark Weinberger
Independent Director
Ronald Williams
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
07/20/2020
Dividend USD 1.01
08/24/2020
04/14/2020
Dividend USD 1.01
05/22/2020
01/02/2020
Dividend USD 0.95
02/24/2020
10/17/2019
Dividend USD 0.95
11/25/2019
07/15/2019
Dividend USD 0.95
08/26/2019
04/25/2019
Dividend USD 0.95
05/24/2019
01/02/2019
Dividend USD 0.9
02/25/2019
10/18/2018
Dividend USD 0.9
11/26/2018
07/16/2018
Dividend USD 0.9
08/27/2018
04/26/2018
Dividend USD 0.9
05/25/2018
01/02/2018
Dividend USD 0.84
02/26/2018
10/19/2017
Dividend USD 0.84
11/27/2017
07/17/2017
Dividend USD 0.84
08/25/2017
04/27/2017
Dividend USD 0.84
05/25/2017
01/03/2017
Dividend USD 0.8
02/24/2017
10/21/2016
Dividend USD 0.8
11/18/2016
07/18/2016
Dividend USD 0.8
08/19/2016
04/28/2016
Dividend USD 0.8
05/20/2016
01/04/2016
Dividend USD 0.75
02/19/2016
10/22/2015
Dividend USD 0.75
11/20/2015
07/20/2015
Dividend USD 0.75
08/21/2015
04/23/2015
Dividend USD 0.75
05/21/2015
01/05/2015
Dividend USD 0.7
02/20/2015
10/16/2014
Dividend USD 0.7
11/21/2014
07/21/2014
Dividend USD 0.7
08/22/2014
04/24/2014
Dividend USD 0.7
05/22/2014
01/02/2014
Dividend USD 0.66
02/21/2014
10/17/2013
Dividend USD 0.66
11/22/2013
07/15/2013
Dividend USD 0.66
08/23/2013
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About JNJ
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Johnson & Johnson stock information, including NYSE:JNJ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNJ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JNJ stock methods without spending real money on the virtual paper trading platform.